• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

EU regulators: We should suspend drugs at suspect Indian facility

March 27, 2017 By Sarah Faulkner

EU regulators: We should suspend drugs at suspect Indian facilityThis week, the European Medicines Agency recommended the suspension of more than 300 generic drug approvals and applications, after they uncovered “unreliable” tests conducted by Micro Therapeutic Research Labs.

The India-based contract research firm is part of the country’s drug-testing industry, which has faced problems with international regulators in recent years.

European officials have reportedly been investigating Micro Therapeutics and the company’s compliance with good clinical practice since Feb. 2016, when Austrian and Dutch authorities raised concerns.

“The inspections identified several concerns at the company’s sites regarding misrepresentation of study data and deficiencies in documentation and data handling,” the agency said, according to Reuters.

The European regulatory agency’s recommendation to suspend medicines tested by Micro Therapeutics will be sent to the European Commission for a legally binding decision that will be valid throughout the E.U.

There is no evidence that the medicine is harmful or doesn’t work as intended, the news outlet reported. Among the pharmaceuticals that would be impacted by the suspension are generic versions of blood pressure pills and pain-relievers.

Pharmaceutical companies often carry out drug-testing at Indian contract research organizations but in the wake of trial data scandals, some drugmakers are bringing their clinical trial programs to the U.S. and Europe, according to industry consultants.

In 2015, Europe banned 700 medicines that were approved based on data provided by India’s massive contract research organization, GVK Biosciences. Regulators have also identified smaller groups as falling short of standards.

Material from Reuters was used in this report. 

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS